Galmed Pharmaceuticals Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Allen Baharaff
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 40.6% |
| CEO tenure | 24.8yrs |
| CEO ownership | n/a |
| Management average tenure | 7.7yrs |
| Board average tenure | 8.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$6m |
| Jun 30 2024 | n/a | n/a | -US$6m |
| Mar 31 2024 | n/a | n/a | -US$6m |
| Dec 31 2023 | US$1m | US$551k | -US$7m |
| Sep 30 2023 | n/a | n/a | -US$8m |
| Jun 30 2023 | n/a | n/a | -US$11m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$1m | US$605k | -US$18m |
| Sep 30 2022 | n/a | n/a | -US$23m |
| Jun 30 2022 | n/a | n/a | -US$25m |
| Mar 31 2022 | n/a | n/a | -US$30m |
| Dec 31 2021 | US$3m | US$632k | -US$32m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$1m | US$503k | -US$29m |
| Sep 30 2020 | n/a | n/a | -US$27m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | -US$23m |
| Dec 31 2019 | US$1m | US$486k | -US$20m |
| Sep 30 2019 | n/a | n/a | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$12m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$2m | US$384k | -US$10m |
| Sep 30 2018 | n/a | n/a | -US$10m |
| Jun 30 2018 | n/a | n/a | -US$12m |
| Mar 31 2018 | n/a | n/a | -US$12m |
| Dec 31 2017 | US$1m | US$384k | -US$12m |
Compensation vs Market: Allen's total compensation ($USD1.36M) is above average for companies of similar size in the German market ($USD471.14K).
Compensation vs Earnings: Allen's compensation has been consistent with company performance over the past year.
CEO
Allen Baharaff (59 yo)
24.8yrs
Tenure
US$1,356,184
Compensation
Mr. Allen Baharaff has been the Chief Executive Officer of Galmed Pharmaceuticals Ltd. since January 2012 and has been its President since March 2015. Mr. Baharaff co-founded the Galmed Pharmaceuticals Ltd...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 24.8yrs | US$1.36m | no data | |
| Chief Financial Officer | 2.8yrs | US$273.81k | 0.0011% € 45.0 | |
| COO & Data Protection Officer | 7.7yrs | US$374.78k | 0.0021% € 82.0 | |
| Chief Accounting Officer | 2.8yrs | US$378.32k | 0.0021% € 82.0 | |
| Chief Scientific Officer | 8.2yrs | US$114.69k | 0% € 0 | |
| Medical Consultant | 7.7yrs | US$382.51k | no data |
7.7yrs
Average Tenure
55.5yo
Average Age
Experienced Management: GPH's management team is seasoned and experienced (7.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | no data | US$1.36m | no data | |
| Lead Independent Director | 10.4yrs | no data | 0.0028% € 111.0 | |
| Independent Director | 7.4yrs | no data | 0% € 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 17.8yrs | no data | 0.0028% € 111.0 | |
| Independent Director | 4.4yrs | no data | 0% € 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
8.9yrs
Average Tenure
63yo
Average Age
Experienced Board: GPH's board of directors are considered experienced (8.9 years average tenure).